American Society of Hematology

Figure 1.

$Figure 1. Molecular targets of antiplatelet agents. US Food and Drug Administration–approved antiplatelet agents are shown in blue boxes. Novel antiplatelet agents in development are shown by red bars. 5-HT, 5-hydroxytryptamine (serotonin); LMWH, low-molecular-weight heparin; NO, nitric oxide; PG, prostaglandin; PI3Kβ, β isoform of phosphoinositide 3-kinase; PSGL-1, P-selectin glycoprotein ligand 1; UFH, unfractionated heparin. Modified with permission from Michelson AD. Nat Rev Drug Discovery. 2010;9:154-169.$

Molecular targets of antiplatelet agents. US Food and Drug Administration–approved antiplatelet agents are shown in blue boxes. Novel antiplatelet agents in development are shown by red bars. 5-HT, 5-hydroxytryptamine (serotonin); LMWH, low-molecular-weight heparin; NO, nitric oxide; PG, prostaglandin; PI3Kβ, β isoform of phosphoinositide 3-kinase; PSGL-1, P-selectin glycoprotein ligand 1; UFH, unfractionated heparin. Modified with permission from Michelson AD. Nat Rev Drug Discovery. 2010;9:154-169.

This Feature Is Available To Subscribers Only